

Levobupivacaine – A Helping Hand for Dental Surgeons

Ananya Roy¹, Mainak Ghosh²

¹Dr Roy's Multispeciality Dental Clinic, Panskura, West Bengal, India.

²Department of Oral and Maxillofacial Surgery, Haldia Institute of Dental Sciences and Research, Haldia, West Bengal, India.

Abstract

Lignocaine 2% with adrenaline 1: 100,000 (Xylocaine) is appeared as the usual to which all other local anesthetics are as compared. From the 1900 to recent times, although bupivacaine is used an awful lot, nevertheless levobupivacaine lagged in the back of though having less cardiotoxicity than bupivacaine. In latest years, levobupivacaine, the natural S (-)-enantiomer of bupivacaine, emerged as a more secure alternative for local anesthesia than its racemic discern.

Keywords: Bupivacaine, Levobupivacaine, Local anesthesia.

INTRODUCTION

In the era of regional anesthesia, levobupivacaine emerged very quickly. Levobupivacaine is the s-isomer of racemic bupivacaine.^[1] It is less cardio, neurotoxic, and equally potent local anesthetic compared to its racemate. It is known to cause less depression of myocardial contractility.^[2]

PHARMACODYNAMICS

Levobupivacaine reversibly blocks the transmission of action potential by inhibiting the passage of sodium through voltage-sensitive ion channels. Excessive dosage can lead to cardiovascular and CNS irregularities.

PHARMACOKINETICS

Volume of distribution and clearance is significantly lower than racemic isomer.^[4] However, unbound fraction being less which accounted for less toxicity. Post-operative increased alpha 1 glycoprotein binds with levobupivacaine further leading to its less toxicity profile.^[5,6] Site of administration, duration of continuous infusion, and/or addition of agents with vasomotor effect have an immense role on systemic uptake of levobupivacaine.^[3]

HISTORY

Bupivacaine is a long-duration local anesthetic. Bupivacaine shows good nerve anesthesia and does not require the addition of epinephrine to prolong its effect which made its use more increasing time by time.^[7] However, the main disadvantage of bupivacaine exposed in the form of cardiotoxicity. It

was believed that local anesthetic toxicity manifests as a progression from mild symptoms to convulsions, eventual cardiac depression, and cardiac arrest.^[8]

STEREOCHEMISTRY

Bupivacaine toxicity has led to explore the area of stereochemistry. Differences between the bupivacaine isomers were first noted by Aberg and Luduena in 1972.^[9,10] It also revealed the increased efficacy of S (-) isomer after skin infiltration.

EFFECT ON DIFFERENT SYSTEMS

Cardiovascular System

Levobupivacaine tested less affinity and electricity of inhibitory effect onto the inactivated state of cardiac sodium channels than dextrobupivacaine.^[11,12] Interactions with the inactivated nation of the sodium channel showed marked stereoselectivity, with a 39% decrease EC₅₀ for inactivated country block through dextrobupivacaine.^[13] Apparent dissociation consistent values of 27.3 mm and 4.1 mm were calculated for dextrobupivacaine and levobupivacaine, indicating dextrobupivacaine to be 7 times more potent in blocking the potassium channel than

Address for correspondence: Dr. Mainak Ghosh,
Department of Oral and Maxillofacial Surgery, Haldia Institute of Dental
Sciences and Research, Haldia, West Bengal, India.
E-mail: mainakghosh@gmail.com

Received: Apr. 03, 2022; **Accepted:** Mar. 01, 2022; **Published:** Apr. 30, 2022

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Roy A, Ghosh M. Levobupivacaine – A Helping Hand for Dental Surgeons. J Res Adv Dent 2022;13(4):1-2.

Access this article online

Website:
www.jrad.co.in

DOI:
<https://doi.org/10.53064/jrad.2022.13.4.189>

levobupivacaine.^[14] Racemic bupivacaine caused a greater than 50% lower in Vmax compared to levobupivacaine and ropivacaine at 30 mm.^[15]

Central Nervous System

The standard deviation of convulsive dose after intravenous levobupivacaine in conscious sheep is 103 (18) mg, appreciably better than the convulsive dose of bupivacaine 85 (11) mg.^[16] The early scientific presentation of toxicity after levobupivacaine seems to consist of relevant anxious signs and symptoms (disorientation, drowsiness, and slurred speech).^[17,18]

ROLE OF LEVOBUPIVACAIN IN DENTAL SURGERY

Initial licensing of levobupivacaine recommends a dose of 150 mg and a maximum dose over 24 h of 400 mg. The expanded safety margin of levobupivacaine would possibly advocate that more drug might be administered in divided doses. Some studies have proven a small growth in length of sensory block with levobupivacaine. Although having a limited degree of clinical impact, this remark may be as a result of the extended relative vasoconstrictive movement of levobupivacaine as compared to bupivacaine.^[19,20] The satisfactory of sensory and motor block seems to be comparable in most studies after same doses of levobupivacaine and bupivacaine. Adding adjunctive analgesics together with epinephrine to local anesthetic also are used to enhance the quality of analgesia and improve safety through reducing the necessities of levobupivacaine. The long period of sensory and motor peripheral blockade after levobupivacaine of approximate 14–16 h diminish the scientific significance of including epinephrine to levobupivacaine. However, epinephrine may additionally assist decrease the potential for systemic toxicity in case of overdose by means of lowering systemic absorption through vasoconstriction or through signaling the accidental intravascular injection. Higher concentrations of levobupivacaine, that is, 0.5%–0.75% speed up the onset, and increase the duration and quality of peripheral nerves blockade. In addition, scientific studies all indicate that levobupivacaine is properly tolerated and has an efficacy equivalent to bupivacaine for each anesthesia and analgesia across a huge spectrum of indications, which include post-operative pain control.

CONCLUSION

In the end, we can safely conclude that levobupivacaine has an ampule efficacy and improved protection profile, a main benefit in local anesthesia. It is to be was hoping that the introduction of this new isomer might be a stepping stone closer to safer local anesthetic practice.

REFERENCES

1. Bouloux GF, Punnia-Moorthy A. Bupivacaine versus lidocaine for third molar surgery: A double-blind, randomized, crossover study. *J Oral Maxillofac Surg* 1999;57:510-4.
2. Sathyanarayana LA, Heggeri VM, Simha PP, Narasimaiah S, Narasimaiah M, Subbarao BK. Comparison of epidural bupivacaine, levobupivacaine and dexmedetomidine in patients undergoing vascular surgery. *J Clin Diagn Res* 2016;10:C13-7.
3. Burlacu CL, Buggy DJ. Update on local anesthetics: Focus on levobupivacaine. *Ther Clin Risk Manag* 2008;4:381-92.
4. Burm AG, van der Meer AD, van Kleef JW, Zeijlmans PW, Groen K. Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. *Br J Clin Pharmacol* 1994;38:125-9.
5. Berrisford RG, Sabanathan S, Mearns AJ, Clarke BJ, Hamdi A. Plasma concentrations of bupivacaine and its enantiomers during continuous extrapleural intercostal nerve block. *Br J Anaesth* 1993;70:201-4.
6. Blake DW, Bjorksten A, Dawson P, Hiscock R. Pharmacokinetics of bupivacaine enantiomers during interpleural infusion. *Anaesth Intensive Care* 1994;22:522-8.
7. Albright GA. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. *Anesthesiology* 1979;51:285-7.
8. Covino BG, Vassallo HG. *Local Anesthetics: Mechanisms of Action and Clinical Use*. New York: Grune and Stratton; 1976.
9. Aberg G. Toxicological and local anaesthetic effects of optically active isomers of two local anaesthetic compounds. *Acta Pharmacol Toxicol (Copenh)* 1972;31:273-86.
10. Luduena FP, Bogado EF, Tullar BF. Optical isomers of mepivacaine and bupivacaine. *Arch Int Pharmacodyn Ther* 1972;200:359-69.
11. Vanhoutte F, Vereecke J, Verbeke N, Carmeliet E. Stereoselective effects of the enantiomers of bupivacaine on the electrophysiological properties of the guinea-pig papillary muscle. *Br J Pharmacol* 1991;103:1275-81.
12. Valenzuela C, Delpón E, Tamkun MM, Tamargo J, Snyders DJ. Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. *Biophys J* 1995;69:418-27.
13. Avery P, Redon D, Schaefer G, Rusy B. The influence of serum potassium on the cerebral and cardiac toxicity of bupivacaine and lidocaine. *Anesthesiology* 1984;61:134-8.
14. Valenzuela C, Delpon E, Tamkun MM, Tamargo J, Snyders DJ. Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. *Biophys J* 1995;69:418-27.
15. Gonzalez T, Arias C. Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: Stereoselective bupivacaine block. *Br J Pharmacol* 2002;137:1269-79.
16. Huang YF, Pryor ME, Mather LE, Veering BT. Cardiovascular and central nervous system effects of intravenous levobupivacaine and bupivacaine in sheep. *Anesth Analg* 1998;86:797-804.
17. Breslin DS, Martin G, Macleod DB, D'ercole F, Grant SA. Central nervous system toxicity following the administration of levobupivacaine for lumbar plexus block: A report of two cases. *Reg Anesth Pain Med* 2003;28:144-7.
18. Crews JC, Rothman TE. Seizure after levobupivacaine for interscalene brachial plexus block. *Anesth Analg* 2003;96:1188-90.
19. Cox CR, Checketts MR, Mackenzie N, Scott NB, Bannister J. Comparison of S(-)-bupivacaine with racemic (RS)-bupivacaine in supraclavicular brachial plexus block. *Br J Anaesth* 1998;80:594-8.
20. Kopacz DJ, Sharrock NE, Allen HW. A comparison of levobupivacaine 0.125%, fentanyl 4 microg/mL, or their combination for patient-controlled epidural analgesia after major orthopedic surgery. *Anesth Analg* 1999;89:1497-503.